An official website of the United States government

This repository is under review for potential modification in compliance with Administration directives.
Citation
Hirst, Kathy (2014). Intraprostatic Injection of Botulinum Toxin for the Management of Benign Prostatic Hyperplasia (MIST) (MIST) (Version 1) [Dataset] NIDDK Central Repository. https://doi.org/10.58020/7xqs-6v33
Data Availability Statement
Data from Intraprostatic Injection of Botulinum Toxin for the Management of Benign Prostatic Hyperplasia (MIST) (MIST) [(Version 1) https://doi.org/10.58020/7xqs-6v33] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.
Acknowledgement Statement
The MIST study was conducted by the study investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The resources from the MIST (https://doi.org/10.58020/7xqs-6v33) study reported here were supplied by NIDDK Central Repository (NIDDK-CR) and are available for request at https://repository.niddk.nih.gov. This manuscript was not prepared under the auspices of the MIST study and does not necessarily reflect the opinions or views of the MIST study, NIDDK-CR, or NIDDK.
Data Package Version
Version 1 (Updated on: May 14, 2014)
Resource Availability
  • Data Available for Request
  • Specimens Not Available
Publications
Explore publications resulting from the use of study resources
View publications (0)

General Description

Benign prostatic hyperplasia (BPH) and lower urinary tract symptoms are bothersome and costly conditions affecting nearly half of men older than age 50 years and 90% of men older than age 80. In the search for more effective noninvasive therapies, the role of the neural activity in BPH has been studied. Botulinum toxin injection has been used for several urological conditions including voiding dysfunction, and studies have shown that intraprostatic injection may be beneficial in lower urinary tract symptoms secondary to BPH.

Eligible men were randomized in a 1:1 ratio to a 100 or a 300 U dose of onabotulinum toxin A. The study was double-blind as to the toxin dose. The drug was injected transrectally into the prostatic peripheral transitional zone with ultrasound guidance. It was administered as 2 cc per lobe in 1 ml aliquots at 2 injection sites for a total of 4 sites.

Men were contacted by telephone at 1 week after treatment, and evaluated in person at 1, 2, 3, 6, 9 and 12 months. Uroflowmetry, vital signs, AUASI and medical conditions were collected or performed at baseline and each visit; transrectal ultrasound and questionnaires on the impact of BPH, bladder function, erectile function and ejaculatory function were administered at baseline, and 3 and 12 months; bladder ultrasound was performed at baseline and 12 months; and physical and digital rectal examination, and prostate specific antigen were determined at baseline, and at 3, 6 and 12 months.

Objectives

To determine whether two different doses (100 U and 300 U) of onabotulinum toxin A injection into the prostate gland demonstrate sufficient improvement in the management of lower urinary symptoms due to BPH to warrant more extensive research.

Outcome Measure

The primary outcome was treatment success at 3 months post-treatment, defined as:

  1. Improvement in the American Urological Association symptom index (AUASI) by at least 30% and/or

  2. Urinary flow rate (Qmax) improvement of more than 30%, each determined from baseline to 3 months after injection.

In addition, two safety criteria also had to be met. A dose failed if either:

  1. Any reported event was determined to be related to the onabotulinum toxin A injection and was considered life threatening, disabling, or fatal

  2. ≥ 40% of the participants reported a moderate or severe side effect related to the botulinum toxin injection.

Eligibility Criteria
  • Male at least 50 years of age
  • Voided volume ≥ 125 ml
  • Maximum urinary flow < 15 ml/sec
  • AUA symptom severity score ≥ 8
  • Patient signed informed consent prior to the performance of any study procedures
  • Patient able to complete the study protocol in the opinion of the investigator
Outcome

A total of 134 men were randomized and treated (68 with 100 units, 66 with 300 units), with 131 assessed at 3 months and 108 assessed at 12 months. Each dose met the 3-month primary outcome criteria. In the 100 unit arm the mean baseline AUASI score of 18.8 decreased by 7.1 and 6.9 at 3 and 12 months, respectively. In the 300 unit arm the baseline of 19.5 decreased by 8.9 and 7.1, respectively. In the 100 unit arm the mean baseline maximum urinary flow rate of 10.0 ml per second increased by 2.5 and 2.2, respectively, and in the 300 unit arm the baseline of 9.6 increased by 2.6 and 2.3, respectively. (J Urol. 2011 Sep;186(3):965-70.)

Research Area

Urologic Diseases

Study Type

Interventional

Study Sites

7

Study Start Date

2006-10

Study End Date

2009-12

Condition

Benign Prostatic Hyperplasia

Keywords

Urinary Flow Rate (Qmax), Digital Rectal Examination, Benign Prostatic Hyperplasia (BPH), Botulinum toxin, Onabotulinum Toxin A, Bladder, American Urological Association Symptom Index (AUASI)

NIDDK Division

Division of Kidney, Urologic, and Hematologic Diseases

134
Participants

Target Population
Adults

Public Documents Table
Document Name
Description
Document Type
File Format
Compliance
Download
If you need accessible versions of documents, please email your request to NIDDK-CRsupport@niddk.nih.gov

Permitted Use(s) of the Resources
  • Use is allowed for health, medical, or biomedical research purposes
Non-Public Documents (0)
There are currently no non-public documents available
Datasets (11)
Datasets Table
Dataset Name
Description
# of Records
# of Variables
File Format(s)
Form SCR1 - Screening Visit 2 Dataset
Contains data from Form SCR1 - Screening Visit 2134sas7bdat (33 KB); csv (9.39 KB)
Form BLAD - Bladder Function Dataset
Contains data from Form BLAD - Bladder Function381sas7bdat (33 KB); csv (9.39 KB)
Form M06 - Visit for Month 6 Dataset
Contains data from Form M06 - Visit for Month 6126sas7bdat (49 KB); csv (13.07 KB)
Form W12M12 - Visits for Week 12 and Month 12 Dataset
Contains data from Form W12M12 - Visits for Week 12 and Month 12253sas7bdat (113 KB); csv (33.7 KB)
Form EREC - Erectile Function Dataset
Contains data from Form EREC - Erectile Function382sas7bdat (41 KB); csv (10.94 KB)
Form EJAC - Ejaculatory Function Dataset
Contains data from Form EJAC - Ejaculatory Function381sas7bdat (33 KB); csv (8.66 KB)
Form AUA - AUA Symptoms Score Dataset
Contains data from Form AUA - AUA Symptoms Score1010sas7bdat (81 KB); csv (24.76 KB)
Form W4W8M9 - Visits at Week 4, Week 8, or Month 12 Dataset
Contains data from Form W4W8M9 - Visits at Week 4, Week 8, or Month 12389sas7bdat (81 KB); csv (26.33 KB)
Form TX0 - Botulinum Toxin Injection Dataset
Contains data from Form TX0 - Botulinum Toxin Injection134sas7bdat (81 KB); csv (28.21 KB)
Form IMPA - BPH Impact Scale Dataset
Contains data from Form IMPA - BPH Impact Scale383sas7bdat (21 KB); csv (7.17 KB)
Form SCR1 - Screening Visit 1 Dataset
Contains data from Form SCR1 - Screening Visit 1134sas7bdat (113 KB); csv (32.8 KB)